Treatment Of Thalassemia
People who have thalassemia minor and show mild symptoms may not require any treatment. However, for people with moderate to severe thalassemia, the following treatments may be required:
1. Vitamin supplements
Vitamin supplements may be required in addition to the regular treatments available to manage thalassemia successfully. For thalassemia minor patients, only vitamin supplements may be recommended to manage the condition.
Folic acid is the most common vitamin recommended to people with thalassemia. It helps build healthy red blood cells and is prescribed to people alongside transfusions and iron chelation therapy.
Apart from this, your doctor may also prescribe Vitamin D and calcium supplements to avoid osteoporosis and build stronger bones.
2. Iron chelation therapy
The hemoglobin present in the red blood cells consists of a high amount of iron. Thus, frequent blood transfusions may result in a build-up of excess iron in the body. This may lead to an iron overload and cause damage to the heart, liver, and other organs of the body.
Even for people who don't have frequent transfusions, an iron overload may still occur. Your doctor may recommend iron chelation therapy to maintain your health and eliminate the excess iron from your body.
Doctors use three common medicines for iron chelation therapy which include:
-
Deferasirox: It is a pill that needs to be taken once daily. It may cause side effects such as nausea and vomiting; however, they are generally short-lived.
-
Deferiprone: This is a medication that is given by mouth. Nausea, vomiting, and diarrhea are relatively common with its use. It is available in both Europe and the United States. It appears to be the most effective agent when the heart is significantly involved.
3. Blood transfusions
Blood transfusion is considered the best treatment for people with thalassemia major. In this treatment, healthy red blood cells with high hemoglobin are transferred into your body using an intravenous (IV) line. This procedure usually takes around 1 to 4 hours.
Red blood cells (RBCs) usually live only up to 120 days. Hence, you may require frequent blood transfusions to manage your condition.
However, if you have beta-thalassemia intermedia, transfusions may be required occasionally. For example, when you have severe anemia or have contracted an infection.
4. Bone marrow transplant
Bone marrow transplant, also known as stem cell transplant, may be considered for your treatment if you have a severe case of thalassemia. Bone marrow is a spongy tissue present inside your bone. The stem cells in the bone marrow are responsible for producing red and other types of blood cells.
A bone marrow transplant is the only effective way to treat thalassemia. For children, it may also eliminate the need for frequent blood transfusions. This procedure requires receiving stem cells from a compatible donor, which are then infused inside your body. Success rates have been in the 80–90% range. Mortality from the procedure is about 3%.
Graft-versus-host disease (GvHD) is one relevant side effect of bone marrow transplantation. Further research is necessary to evaluate whether mesenchymal stromal cells can be used as prophylaxis or treatment for GvHD.
5. Hemoglobin (Hb) inducer drugs
Thalassemia patients who do not respond well to blood transfusions can take hydroxyurea or thalidomide, and sometimes a combination of both. Hydroxyurea is the only FDA approved drug for thalassemia. Patients who took 10 mg/kg of hydroxyurea every day for a year had significantly higher hemoglobin levels, and it was a well-tolerated treatment for patients who did not respond well to blood transfusions. Another hemoglobin-inducer includes thalidomide, although it has not been tested in a clinical setting. The combination of thalidomide and hydroxyurea resulted in hemoglobin levels increasing significantly in transfusion-dependent and non-transfusion dependent patients
6. Gene therapy
Gene therapy is being studied for thalassemia.The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. The HSCs then have a beta-globin gene added using a lentiviral vector. After destroying the affected person's bone marrow with a dose of chemotherapy (a myeloablative conditioning regimen), the altered HSCs are infused back into the affected person where they become engrafted in the bone marrow where they proliferate. This potentially results in a progressive increase in hemoglobin A2 synthesis in all subsequent developing red blood cells, with resultant resolution of the anemia.
While one person with beta thalassemia has no longer required blood transfusions following treatment within a research trial, it is not an approved treatment as of 2018.